Literature DB >> 29322801

Paraoxonase activity in sera of patients with non-alcoholic fatty liver disease.

M Fedelesova, V Kupcova, J Luha, L Turecky.   

Abstract

The results of our study showed significantly decreased levels of PON1 in patients with chronic liver diseases (controls 185 ± 14 U/l, NAFLD 160 ± 15 U/l, chronic hepatitis 99 ± 18 U/l, cirrhosis 52 ± 11 U/l). There were significant correlations of PON activities with standard liver function tests (Tab. 1, Ref. 5).

Entities:  

Keywords:  fatty liver disease; oxidative stress NAFLD.; paraoxonase

Mesh:

Substances:

Year:  2017        PMID: 29322801     DOI: 10.4149/BLL_2017_134a

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  4 in total

1.  Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival.

Authors:  Zheng Yu; Qifeng Ou; Fan Chen; Jiong Bi; Wen Li; Jieyi Ma; Rongchang Wang; Xiaohui Huang
Journal:  J Transl Med       Date:  2018-11-26       Impact factor: 5.531

Review 2.  Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders.

Authors:  Maria João Meneses; Regina Silvestre; Inês Sousa-Lima; Maria Paula Macedo
Journal:  Int J Mol Sci       Date:  2019-08-19       Impact factor: 5.923

3.  Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD).

Authors:  Robin C Su; Apurva Lad; Joshua D Breidenbach; Thomas M Blomquist; William T Gunning; Prabhatchandra Dube; Andrew L Kleinhenz; Deepak Malhotra; Steven T Haller; David J Kennedy
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

4.  Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.

Authors:  Kazuhiko Kotani; Jun Watanabe; Kouichi Miura; Alejandro Gugliucci
Journal:  Molecules       Date:  2021-04-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.